Hexyme drug with folic acid in the clearance of high-risk HPV virus

Comparison of the effect of Hexyme drug with folic acid in the clearance of high-risk HPV virus

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20240424061554N1

Enrollment

120

Registered

2024-05-04

Start date

2024-05-21

Completion date

Unknown

Last updated

2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hpv virus. High risk human papillomavirus (HPV) DNA test positive from female genital organs

Interventions

Intervention 1: Intervention group: Hexyme group (capsule containing 3 grams of Lentilula edodes mycelia extract once a day for 6 months). Made by Ashbal Chemical Company. Intervention 2: Intervention

Eligibility

Sex/Gender

Female

Age

25 Years to 50 Years

Inclusion criteria

Inclusion criteria: ?Informed consent Ages between 25 and 50 Negative pregnancy test High risk HPV infection

Exclusion criteria

Exclusion criteria: History of hepatitis (autoimmune, A, B or C) or positive antigen Pregnant or breastfeeding Medical history of myocardial infarction, unstable angina, heart failure, or uncontrolled blood pressure (more than 140.90 mmHg) within 6 months before the intervention. Any history of infection or current active malignancy

Design outcomes

Primary

Measure	Time frame
Virus clearance. Timepoint: 6 months later. Method of measurement: Physical examination and laboratory test.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNiloofar Shahi

Esfahan University of Medical Sciences

drnilofar.shahi@gmail.com+98 913 421 2825

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026